|
GenVec Reports Fourth Quarter and Year-End 2009 Financial Results
|
| 03/11/10 |
|
GenVec To Present at the Roth 22nd Annual Orange County Growth Stock Conference
|
| 03/09/10 |
|
GenVec To Host Fourth Quarter and Year-End 2009 Earnings Call and Webcast
|
| 03/05/10 |
|
New Research Reveals Mechanism By Which TNFerade™ Suppresses Metastases
|
| 03/03/10 |
|
GenVec Announces Contract with the Department of Homeland Security
|
| 02/19/10 |
|
GenVec To Present at the 12th Annual BIO CEO & Investor Conference
|
| 02/01/10 |
|
GenVec Announces Registered Offering of $28 Million in Common Stock and Warrants
|
| 01/27/10 |
|
Data from TNFerade™ Esophageal Cancer Study Presented at 2010 ASCO Gastrointestinal Cancer Symposium
|
| 01/22/10 |
|
GenVec Enters Collaboration on Hearing Loss Treatments with Leading Global Pharmaceutical Company
|
| 01/19/10 |
|
Key Event Occurs in GenVec's PACT Trial
|
| 01/15/10 |
|
GenVec Regains Compliance With NASDAQ Listing Requirements
|
| 01/07/10 |
|
GenVec To Present at Biotech Showcase 2010
|
| 01/05/10 |
|
GenVec Announces Third Quarter 2009 Financial Results
|
| 11/05/09 |
|
GenVec Signs New Contract To Support HIV and Influenza Vaccine Development
|
| 11/05/09 |
|
FDA Grants Orphan Drug Designation for TNFerade™
|
| 11/04/09 |
|
GenVec To Present at Merriman Curhan Ford's Investor Summit 2009
|
| 11/03/09 |
|
GenVec Announces Third Quarter 2009 Results Conference Call
|
| 10/28/09 |
|
GenVec To Present at the BIO Investor Forum
|
| 10/22/09 |
|
GenVec Receives National Cancer Institute Grant to Expand Cancer Program
|
| 09/30/09 |
|
GenVec Receives Fourth-Year Funding from NIAID for HIV Vaccine Contract
|
| 09/24/09 |
|
GenVec Receives NASDAQ Notice of Minimum Bid Price Non-Compliance
|
| 09/16/09 |
|
GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
|
| 08/27/09 |
|
GenVec Receives An Approximately $2.5 Million Grant To Support Novel Cell Line Development
|
| 08/25/09 |
|
GenVec Reports Second Quarter 2009 Financial Results
|
| 08/06/09 |
|
GenVec Announces Second Quarter 2009 Results Conference Call
|
| 07/30/09 |
|
GenVec Receives Grant for Malaria Vaccine Program
|
| 07/29/09 |
|
GenVec Expands Contract Supporting Malaria Vaccine Program
|
| 07/27/09 |
|
TNFerade™ Phase III Data Presented at ASCO
|
| 06/01/09 |
|
GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
|
| 05/28/09 |
|
GenVec Reports First Quarter 2009 Financial Results
|
| 05/07/09 |
|
GenVec Announces First Quarter 2009 Results Conference Call
|
| 04/30/09 |
|
GenVec Reports Fourth Quarter and Year-End 2008 Financial Results
|
| 03/12/09 |
|
GenVec To Host Fourth Quarter and Year-End 2008 Earnings Call and Webcast
|
| 03/05/09 |
|
GenVec To Present at the 11th Annual BIO CEO & Investor Conference
|
| 02/03/09 |
|
GenVec Reduces Costs To Preserve Capital
|
| 01/29/09 |
|
GenVec Announces Multiple Presentations at the American Society of Tropical Medicine and Hygiene Meeting
|
| 12/05/08 |
|
GenVec Announces Interim Survival Data in Pivotal Trial of TNFerade(TM) in Locally Advanced Pancreatic Cancer
|
| 11/19/08 |
|
TNFerade™ Receives FDA Fast Track Designation for Treatment of Pancreatic Cancer
|
| 11/11/08 |
|
GenVec Reports Third Quarter 2008 Financial Results
|
| 11/06/08 |
|
GenVec Announces Third Quarter 2008 Results Conference Call
|
| 10/31/08 |
|
GenVec Receives Third-Year Funding from NIAID for HIV Vaccine Contract
|
| 10/02/08 |
|
GenVec To Present at Merriman Curhan Ford's Investor Summit 2008 on September 15th
|
| 09/08/08 |
|
GenVec Reports Second Quarter 2008 Financial Results
|
| 08/07/08 |
|
GenVec Announces Second Quarter 2008 Results Conference Call
|
| 08/01/08 |
|
GenVec Receives Continued Funding From the U.S. Department of Homeland Security For Vaccine Program
|
| 07/29/08 |
|
GenVec Completes $17 Registered Direct Offering
|
| 06/12/08 |
|
Promising Data Presented on GenVec Malaria Vaccine Program
|
| 06/12/08 |
|
GenVec Announces Registered Offering of $17 Million in Common Stock and Warrants
|
| 06/06/08 |
|
Encouraging Findings from TNFerade™ Head and Neck Cancer Study Presented at ASCO
|
| 05/31/08 |
|
GenVec Presents Encouraging Data on TNFerade™ in Esophageal Cancer
|
| 05/29/08 |
|
GenVec Receives Grant for PEDF Program
|
| 05/21/08 |
|
GenVec Reports First Quarter 2008 Financial Results
|
| 05/08/08 |
|
GenVec Announces Grant For RSV Vaccine Program
|
| 05/07/08 |
|
GenVec Announces First Quarter 2008 Results Conference Call
|
| 05/02/08 |
|
GenVec Presents New Research on TNFerade™
|
| 04/15/08 |
|
GenVec Receives Grant for Malaria Vaccine Program
|
| 04/03/08 |
|
GenVec Reports Fourth Quarter and Year-End 2007 Financial Results
|
| 03/13/08 |
|
GenVec To Host Fourth Quarter and Year-End 2007 Earnings Call and Webcast
|
| 03/07/08 |
|
GenVec Announces Grant for HSV-2 Vaccine Program
|
| 03/06/08 |
|
GenVec To Present at the 10th Annual BIO CEO Conference
|
| 02/05/08 |
|
GenVec Announces Manufacturing Agreement for TNFerade™
|
| 01/24/08 |
|
GenVec Appoints Kevin M. Rooney to Board of Directors
|
| 01/18/08 |
|
GenVec Announces Protocol Changes for PACT Study After Discussions with FDA
|
| 01/03/08 |
|
GenVec Annouces NIH Funding for Balance and Hearing Loss Program
|
| 12/18/07 |
|
GenVec Reports Third Quarter 2007 Financial Results
|
| 11/07/07 |
|
GenVec Announces Third Quarter 2007 Results Conference Call
|
| 10/31/07 |
|
Encouraging Preliminary Data from TNFerade™ Phase II Rectal Cancer Study Presented at ASTRO Meeting
|
| 10/31/07 |
|
GenVec to Present at Rodman & Renshaw 9th Annual Healthcare Conference
|
| 10/30/07 |
|
GenVec Receives Additional Funding for 7th Year of HIV Vaccine Program
|
| 10/19/07 |
|
GenVec Named to Deloitte's Technology Fast 50 for Maryland
|
| 10/03/07 |
|
GenVec Receives Second-Year Funding From NIAID for HIV Vaccine Contract
|
| 10/02/07 |
|
GenVec To Present at BIO Investor Forum
|
| 10/02/07 |
|
Harold R. Werner To Resign From GenVec's Board of Directors
|
| 09/21/07 |
|
GenVec Technology Demonstrates Selective Anti-Cancer Activity
|
| 09/20/07 |
|
Promising Early Data from Phase I/II Clinical Trial Using GenVec Vaccine Presented at Malaria Conference
|
| 09/19/07 |
|
GenVec To Develop New Malaria Vaccine For The U.S. Military
|
| 09/10/07 |
|
GenVec Announces Increased Funding for FMD Vaccine Program from the U.S. Department of Homeland Security
|
| 09/05/07 |
|
Encouraging Phase II Data on HIV Vaccine Utilizing GenVec Technologies Presented at Seattle AIDS Conference
|
| 08/23/07 |
|
GenVec Reports Second Quarter 2007 Financial Results
|
| 08/07/07 |
|
GenVec Announces Second Quarter 2007 Results Conference Call
|
| 07/31/07 |
|
First Ad35-Based HIV-1 Vaccine Enters Phase I Clinical Trial at NIH
|
| 06/21/07 |
|
GenVec To Host Investor Conference Call To Review Data Presented at ASCO
|
| 06/05/07 |
|
GenVec Announces Update of Safety and Efficacy Data From Pivotal Phase II/III PACT Study of TNFerade (TM) at ASCO
|
| 06/04/07 |
|
GenVec Annouces Multiple Presentations at The American Society for Gene Therapy Annual Meeting
|
| 05/30/07 |
|
GenVec Added to the Nasdaq Biotechnology Index (NBI)
|
| 05/14/07 |
|
GenVec Presents Research on New Ad35 Adnovector at ARVO
|
| 05/10/07 |
|
GenVec Reports First Quarter 2007 Financial Results
|
| 05/09/07 |
|
GenVec Announces Issuance of TNFerade (TM) Therapeutic Regimen Patent
|
| 05/08/07 |
|
GenVec Announces First Quarter 2007 Results Conference Call
|
| 05/02/07 |
|
GenVec Announces Additional Funding for Malaria Vaccine Program From the PATH Malaria Vaccine Initiative
|
| 05/01/07 |
|
GenVec Appoints Marc R. Schneebaum to Board of Directors
|
| 04/19/07 |
|
GenVec Announces New Research at AACR on Selectivity and Mechanism of Action of TNF-Based Anti Cancer Therapy
|
| 04/17/07 |
|
GenVec to Present at BioCentury and Thomson Financial's Future Leaders in the Biotech Industry Conference
|
| 03/22/07 |
|
GenVec Signs Cooperative Research and Development Agreement (CRADA) with the National Institute of Allergy and Infectious Diseases (NIAID) to Develop RSV Vaccines
|
| 03/20/07 |
|
GenVec Reports Fourth Quarter and 2006 Year End Financial Results
|
| 03/14/07 |
|
GenVec Invites You to Join Its Fourth Quarter and Year-End Earnings Call and Webcast
|
| 03/07/07 |
|
GenVec to Present at Cowen and Company 27th Annual Health Care Conference
|
| 03/05/07 |
|
GenVec to Present at the 9th Annual BIO CEO & Investor Conference
|
| 02/06/07 |
|
GenVec Proprietary Adenovector and Gene Used to Restore Balance Function in Mice
|
| 02/06/07 |
|
GenVec Announces Vaccine Collaboration with the Department of Homeland Security
|
| 02/01/07 |
|
GenVec Announces First Patient Treated With TNFerade (TM) for Head and Neck Cancer at University of Chicago
|
| 01/26/07 |
|
First Malaria Vaccine Trial Launched Under GenVec/U.S. Navy Collaboration
|
| 01/17/07 |
|
GenVec Receives Clearance from FDA for EUS Administration of TNFerade™
|
| 01/11/07 |
|
GenVec Closes $19.7 Million Registered Direct Offering
|
| 12/22/06 |
|
GenVec Announces Registered Offering of $19.7 Million in Common Stock
|
| 12/20/06 |
|
GenVec Announces Efficacy Update in Phase II/III Clinical Trial of TNFerade (TM) in Locally Advanced Pancreatic Cancer
|
| 12/19/06 |
|
Positive Clinical Trial Results Using GenVec's Adenovirus Vector Technology to Deliver a Candidate HIV-1 Vaccine Reported in the Journal of Infectious Diseases
|
| 12/15/06 |
|
GenVec Announces Completion of Interim Safety Data Analysis for Phase II/III Trial With TNFerade (TM) in Pancreatic Cancer
|
| 12/14/06 |
|
GenVec Reports Third Quarter 2006 Financial Results
|
| 11/08/06 |
|
GenVec Invites You to Join Its Third Quarter 2006 Earnings Call and Webcast
|
| 11/01/06 |
|
GenVec to Present at Rodman & Renshaw 8th Annual Healthcare Conference
|
| 10/26/06 |
|
GenVec HIV Vaccine Program to Receive Additional Funding
|
| 10/10/06 |
|
GenVec Names Mark O. Thornton, MD, MPH, PHD as Senior Vice President, Clinical Development
|
| 10/09/06 |
|
GenVec Announces New $52 Million Contract With NIH/NIAID Vaccine Research Center to Support HIV Vaccine Production
|
| 10/05/06 |
|
GenVec Names Douglas J. Swirsky as Chief Financial Officer
|
| 09/19/06 |
|
Stelios Papadopoulos to Resign from GenVec’s Board of Directors
|
| 09/08/06 |
|
Data From Multiple Phase I Trials Incorporating GenVec Technology Presented At International AIDS Conference
|
| 08/31/06 |
|
GenVec Receives NIAID Biodefense Program Grant for Development of Broadly Applicable Vaccine Technology
|
| 08/29/06 |
|
GenVec Vaccine Technology Enters First HIV Human Therapeutic Clinical Trials at Vaccine Research Center at NIH
|
| 08/22/06 |
|
GenVec Announces Resignation of Jeffrey W Church as Chief Financial Officer
|
| 08/15/06 |
|
GenVec Reports Second Quarter 2006 Financial Results
|
| 08/08/06 |
|
GenVec Invites You To Join Its Second Quarter 2006 Earnings Call And Webcast
|
| 08/02/06 |
|
Long-Term Results from TNFerade(TM) Pancreatic Cancer Study and UPdated Survival Results from TNFerade(TM) Esophageal Cancer Study Both Reported at Digestive Disease Week
|
| 05/23/06 |
|
GenVec to Present at Rodman & Renshaw 3rd Annual Global Healthcare Conference
|
| 05/10/06 |
|
GenVec Reports First Quarter 2006 Financial Results
|
| 05/09/06 |
|
GenVec Invites You To Join Its First Quarter 2006 Earnings Call And Webcast
|
| 05/02/06 |
|
GenVec Receives Additional Funding For Malaria Vaccine Program
|
| 04/27/06 |
|
GenVec Appoints New Head of Clinical Operations
|
| 04/04/06 |
|
TNFerade Reduces Metastasis in Animal Model of Melanoma
|
| 04/04/06 |
|
GenVec Begins Phase II Melanoma Study with TNFerade
|
| 03/28/06 |
|
GenVec Reports Fourth Quarter and 2005 Year End Financial Results
|
| 03/15/06 |
|
GenVec Expands TNFerade Phase II Pancreatic Cancer Study Into Phase II/III Trial
|
| 03/15/06 |
|
GenVec Invites You To Join Its Fourth Quarter and Year-End 2005 Earnings Call and Webcast
|
| 03/08/06 |
|
GenVec Completes Enrollment in AdPEDF Clinical Study for Macular Degeneration
|
| 03/07/06 |
|
GenVec to Webcast Presentation at the Cowen & Co. 26th Annual Healthcare Conference
|
| 03/02/06 |
|
GenVec Announces $1.7 Million Collaboration For Continued Development of a Foot and Mouth Disease Vaccine
|
| 03/01/06 |
|
GenVec Names Russell Wesdyk Vice President of Business Development and Strategic Planning
|
| 02/13/06 |
|
GenVec’s CEO To Participate In Panel Session On Pancreatic Cancer Treatment Strategies At The BIO CEO & Investor Conference
|
| 02/10/06 |
|
GenVec and the NIH's Vaccine Research Center to Expand Current Collaboration to Include Preliminary Development of an Influenza Vaccine
|
| 02/09/06 |
|
GenVec Macular Degeneration Study and Supporting Editorial Published in February Issue of Human Gene Therapy
|
| 02/06/06 |
|
Long-Term Survival Data from GenVec's Phase II Study of TNFerade(TM) in Esophageal Cancer Presented at ASCO GI
|
| 01/27/06 |
|
GenVec Completes Previously Announced Sale of Myoblast Cell Therapy Program
|
| 12/29/05 |
|
GenVec Announces Webcast of CFO Presentation at S.G. Cowen 6th Annual Global Healthcare Conference
|
| 11/08/05 |
|
GenVec Announces Webcast of CEO Presentation at Rodman & Renshaw Techvest 7th Annual Healthcare Conference
|
| 11/04/05 |
|
GenVec Reports Third Quarter 2005 Financial Results
|
| 11/02/05 |
|
GenVec to Host Third Quarter Earnings Call and Webcast on November 2, 2005
|
| 10/26/05 |
|
GenVec Announces Plan to Sell Myoblast Cell Therapy Program to a Newly Formed Company
|
| 10/18/05 |
|
Vaccine Research Center (VRC) Initiates Phase II Testing of an HIV Vaccine Developed in Collaboration with GenVec
|
| 10/11/05 |
|
GenVec Announces $9.9 Million Increase in Funding for HIV Vaccine Collaboration with Vaccine Research Center
|
| 10/03/05 |
|
GenVec Completes $15.2 Million Financing
|
| 09/26/05 |
|
GenVec Announces Commitment for Additional 400,000 Shares of Common Stock
|
| 09/21/05 |
|
GenVec to Raise $14.5 Million in Registered Direct Offering of Common Stock
|
| 09/21/05 |
|
Encouraging Immune Response Seen in "Prime/Boost" Phase I HIV Vaccine Study
|
| 09/06/05 |
|
GenVec Reports Second Quarter 2005 Financial Results
|
| 08/03/05 |
|
GenVec to Host Second Quarter Earnings Call and Webcast on August 3, 2005
|
| 07/27/05 |
|
GenVec Appoints Thomas A. Davis, M.D., Chief Medical Officer
|
| 07/26/05 |
|
GenVec Receives FDA Clearance to Resume Phase II Trial in Rectal Cancer with TNFerade(TM)
|
| 05/24/05 |
|
GenVec to Present at the Fourth Annual Needham & Company Biotechnology Conference
|
| 05/23/05 |
|
Update on Dose-Escalation Trial of TNFerade(TM) in Pancreatic Cancer Shows Dose-Dependent Improvements in Tumor Shrinkage and Resectability and Patient Survival
|
| 05/16/05 |
|
GenVec to Present at Rodman & Renshaw Techvest 2nd Annual Global Healthcare Conference
|
| 05/02/05 |
|
GenVec to Present at Deutsche Bank's 30th Annual Health Care Conference
|
| 05/02/05 |
|
GenVec Reports First Quarter 2005 Financial Results
|
| 04/27/05 |
|
GenVec Invites You to Join its First Quarter 2005 Earnings Call and Webcast
|
| 04/25/05 |
|
GenVec Reports Preclinical Research at AACR Showing TNFerade™ Effective Against Metastases in Melanoma Model and Demonstrating Targeting in Ovarian Cancer Model
|
| 04/20/05 |
|
Results from Phase I HIV Vaccine Study Reported at Keystone Symposium
|
| 04/15/05 |
|
GenVec to Present at SG Cowen & Co 25th Annual Healthcare Conference
|
| 03/10/05 |
|
GenVec Reports Fourth Quarter and 2004 Year End Financial Results
|
| 03/09/05 |
|
Three Year Phase I Myoblast Cell Transplantation Study Data Presented at American College of Cardiology Scientific Sessions
|
| 03/08/05 |
|
GenVec Launches Phase IIB Trial in Patients With Severe Coronary Artery Disease
|
| 03/02/05 |
|
GenVec Invites You to Join its Fourth Quarter and Year-End 2004 Earnings Call and Webcast
|
| 03/01/05 |
|
GenVec Expands Clinical Testing of AdPEDF for Macular Degeneration
|
| 02/22/05 |
|
GenVec to Participate in Focus Session at the Bio CEO & Investor Conference
|
| 02/18/05 |
|
GenVec Announces Publication of Hearing Loss Research
|
| 02/14/05 |
|
GenVec Receives FDA Clearance to Proceed with the Randomized Portion of the Phase II Clinical Study Of TNFerade™ in Pancreatic Cancer
|
| 02/11/05 |
|
GenVec Expands Malaria Vaccine Program Under U.S. Naval Medical Research Center Contract
|
| 01/20/05 |
|
NIH Begins Second Phase I Clinical Trial of HIV Vaccine Produced in Collaboration With GenVec
|
| 01/19/05 |
|
Next Generation HIV Vaccine Research Collaboration Between Vaccine Research Center and GenVec Under New Contract Extension
|
| 01/12/05 |
|
GenVec Receives National Eye Institute Grant for Its Ocular Program
|
| 12/07/04 |
|
GenVec Expands PEDF Rights for All Ocular Diseases From the National Institutes of Health
|
| 11/30/04 |
|
Nita U. Patel, Ph.D. Joins GenVec as Vice President, Regulatory Affairs
|
| 11/23/04 |
|
Follow-Up Data from GenVec's Myoblast Cell Therapy for Congestive Heart Failure Presented at American Heart Association 2004 Scientific Sessions
|
| 11/08/04 |
|
GenVec Announces Third Quarter 2004 Financial Results
|
| 11/04/04 |
|
GenVec to Present at Rodman & Renshaw Techvest 6th Annual Healthcare Conference
|
| 10/22/04 |
|
GenVec Reports Encouraging Findings From Phase 1 Trial of AdPEDF in Patients With Wet Age-Related Macular Degeneration
|
| 10/22/04 |
|
GenVec to Present at BIO Emerging Company Investor Forum
|
| 10/13/04 |
|
GenVec Announces Clinical Hold on TNFerade(TM) Trials
|
| 10/07/04 |
|
Interim Results of Dose Escalation Study of TNFerade(TM) Presented at International Cancer Meeting
|
| 10/01/04 |
|
Positive Results for the Phase I Study of TNFerade(TM) in Patients with Soft Tissue Sarcoma Published in Clinical Cancer Research
|
| 09/10/04 |
|
USDA Agency to Evaluate GenVec's Technology for Prevention of Foot and Mouth Disease
|
| 09/01/04 |
|
GenVec Announces Second Quarter 2004 Financial Results and Updates on Clinical Programs
|
| 08/05/04 |
|
GenVec and NIH Move HIV Vaccine Candidate Into Human Clinical Trials
|
| 07/28/04 |
|
GenVec to Present at Needham & Company Biotechnology Conference
|
| 06/09/04 |
|
GenVec Presents Promising Survival Data for TNFerade(TM) in Phase II Pancreatic Cancer Study
|
| 06/07/04 |
|
GenVec Presents Update on TNFerade(TM) at Digestive Disease Week
|
| 05/17/04 |
|
GenVec to Present at Rodman & Renshaw Techvest Global Healthcare Conference
|
| 05/05/04 |
|
GenVec Announces First Quarter 2004 Financial Results
|
| 04/29/04 |
|
GenVec Presents Data from Phase I Clinical Study in Patients with Wet Age-Related Macular Degeneration
|
| 04/28/04 |
|
GenVec Completes $12.6 Million Sale of Common Stock
|
| 04/16/04 |
|
GenVec Offering Up to 4,000,000 Shares of Common Stock in a Best Efforts Offering
|
| 04/14/04 |
|
GenVec, U.S. Naval Medical Research Center and Path's Malaria Vaccine Initiative Partner to Expand Malaria Vaccine Efforts
|
| 03/31/04 |
|
GenVec Reports Fourth Quarter and 2003 Financial Results
|
| 03/10/04 |
|
GenVec's Myoblast Cell Transplantation Program Highlighted at American College of Cardiology Scientific Sessions
|
| 03/09/04 |
|
GenVec to Present at SG Cowen 24th Annual Health Care Conference
|
| 03/04/04 |
|
GenVec and the National Institutes Of Health (NIH) Expand Contract to Include Manufacturing For SARS Vaccine Candidate
|
| 02/25/04 |
|
GenVec to Present Early Pre-Clinical Data at Association For Research in Otolaryngology Meeting
|
| 02/24/04 |
|
GenVec to Participate in Panel Discussions at BIO CEO & Investor Conference
|
| 02/18/04 |
|
TNFerade(TM) Clinical Study Published In The Journal of Clinical Oncology
|
| 02/17/04 |
|
GenVec Receives Patent for Cardiac Disease
|
| 02/04/04 |
|
GenVec Presents New Data on TNFerade(TM) for Pancreatic Cancer
|
| 01/23/04 |
|
GenVec to Present at ASCO Gastrointestinal Cancers Symposium
|
| 01/21/04 |
|
GenVec Enters Into Collaboration With Cordis Corporation
|
| 01/08/04 |
|
GenVec to Conduct Conference Call
|
| 01/08/04 |
|
GenVec and the National Institutes of Health (NIH) Expand Manufacturing Contract to Include Late-Stage Clinical Manufacturing for HIV Vaccine
|
| 01/06/04 |
|
GenVec Receives SBIR Grants for PEDF ProteinResearch in Macular Degeneration
|
| 12/09/03 |
|
GenVec Announces Presentations for Lead Oncology Product Candidate, TNFerade(TM)
|
| 11/19/03 |
|
Update on Progress of GenVec's Phase 1 Clinical Trial In Patients With Wet Age-Related Macular Degeneration
|
| 11/17/03 |
|
GenVec to Present at BIO-Europe and Harris Nesbitt Conferences
|
| 11/13/03 |
|
GenVec Presents Phase 1 Safety Results in Myoblast Cell Transplantation Program
|
| 11/12/03 |
|
GenVec Expands Contract With the National Institutes of Health
|
| 11/05/03 |
|
GenVec Announces Third Quarter 2003 Financial Results
|
| 11/04/03 |
|
National Cancer Institute to Conduct Phase II Clinical Study Using TNFerade(TM) in Rectal Cancer
|
| 10/23/03 |
|
GenVec Announces U.S. Patents for TNFerade(TM) and TNF Product Candidates Targeting Metastatic Cancer
|
| 09/03/03 |
|
GenVec Completes Merger With Diacrin, Inc.
|
| 08/21/03 |
|
GenVec Receives Maryland Industrial Partnerships (MIPS) Award
|
| 08/19/03 |
|
GenVec Announces Second Quarter 2003 Financial Results
|
| 07/31/03 |
|
GenVec Receives U.S. Patent for TNFerade(TM)
|
| 07/15/03 |
|
GenVec Announces Early Research Efforts for Inner Ear Disorders
|
| 06/04/03 |
|
GenVec Presents Preliminary Dose Escalation Data from Study Combining TNFerade(TM) with Chemotherapy and Radiation in Patients With Locally Advanced Pancreatic Cancer
|
| 06/02/03 |
|
Combined Use of TNFerade(TM) and Radiation Therapy Produced 85% Response Rate in Phase I Study of Patients with Soft Tissue Sarcoma
|
| 06/02/03 |
|
GenVec to Present at Needham & Company Second Annual Biotechnology Conference
|
| 05/29/03 |
|
Diacrin Announces First Quarter Results
|
| 05/07/03 |
|
GenVec to Present Preclinical Data on its Antiangiogenic Agent to Treat Vision Loss at Leading Ophthalmology Meeting
|
| 05/05/03 |
|
GenVec Signs Letter of Intent With the National Institutes Of Health for Second Agreement to Combat SARS
|
| 04/29/03 |
|
GenVec and National Institutes of Health Begin Work on SARS Vaccine
|
| 04/24/03 |
|
GenVec Announces First Quarter 2003 Financial Results
|
| 04/23/03 |
|
Genvec and Diacrin to Merge
|
| 04/15/03 |
|
GenVec Announces Two Clinical Data Presentations on Lead Product Candidate TNFerade
|
| 03/26/03 |
|
GenVec Receives U.S. Patent for Therapeutic Angiogenesis in Humans
|
| 03/20/03 |
|
GenVec Reports Fourth Quarter and Fiscal Year End 2002 Financial Results
|
| 03/11/03 |
|
Diacrin Announces Fourth Quarter and Year End Results
|
| 03/06/03 |
|
GenVec to Receive Approximately $2 Million From Agreement With U.S. Naval Medical Research Center to Develop Vaccines Against Diseases of Military Importance
|
| 01/09/03 |
|
GenVec Announces Product Candidate for the Treatment of Poor Blood Flow in the Legs Did Not Meet Clinical Endpoints
|
| 01/07/03 |
|
GenVec to Present at 21st Annual JPMorgan H&Q Healthcare Conference
|
| 01/03/03 |
|
GenVec Files Shelf Registration Statement
|
| 12/19/02 |
|
GenVec, Inc. Appoints David P. Wright President and Chief Operating Officer
|
| 12/18/02 |
|
GenVec and Fuso Pharmaceuticals Announce New Cancer Collaboration
|
| 12/11/02 |
|
GenVec Announces Year-End Conference Call
|
| 12/09/02 |
|
GenVec Begins Phase I Clinical Trial in Patients With Age-Related Macular Degeneration
|
| 11/26/02 |
|
GenVec Announces Interim Phase I Data on TNFerade(TM) In Patients With Soft Tissue Sarcoma
|
| 11/25/02 |
|
BIOBYPASS(R) Shows Statistically Significant Positive Results In Patients With Severe Coronary Artery Disease
|
| 11/20/02 |
|
GenVec to Present Phase II Clinical Data on BIOBYPASS(R) In Patients With Severe Coronary Artery Disease
|
| 11/18/02 |
|
Diacrin Announces Presentation of Data From Clinical Trials at AHA Conference
|
| 11/14/02 |
|
GenVec Announces Commencement of Phase II Clinical Trial of TNFerade(TM) in Patients with Esophageal Cancer
|
| 11/14/02 |
|
Diacrin Announces Resignation of Board Member
|
| 11/12/02 |
|
GenVec to Present Final Data From Phase Ib Clinical Trial of TNFerade In Patients With a Variety of Solid Tumors
|
| 11/08/02 |
|
Gene Therapy in Combination With Radiation Shows Notable Dose-Related Tumor Shrinkage in Phase Ib Human Trials
|
| 11/08/02 |
|
Diacrin Announces Third Quarter Results
|
| 11/07/02 |
|
GenVec Announces Third Quarter 2002 Financial Results
|
| 10/31/02 |
|
GenVec Elects the Honorable Barbara Hackman Franklin To Board of Directors
|
| 10/02/02 |
|
GenVec Completes Patient Enrollment in Phase I Clinical Trial of TNFerade in Soft Tissue Sarcoma
|
| 09/24/02 |
|
Diacrin Licenses its Muscle Cell Transplantation Technology for Cardiac Disease to Terumo for Japan
|
| 09/05/02 |
|
GenVec, Inc. Appoints David W. Robinson As Vice President of Marketing & Sales
|
| 08/26/02 |
|
Diacrin Announces Second Quarter Results
|
| 08/13/02 |
|
Gene Therapy May Enhance Effectiveness of Chemotherapeutic Agents
|
| 08/07/02 |
|
GenVec Announces Second Quarter 2002 Financial Results
|
| 08/01/02 |
|
GenVec Begins Phase IIb Trials Of TNFerade in Patients With Pancreatic Cancer
|
| 07/17/02 |
|
GenVec and DirectGene Sign Collaboration and License Agreement To Develop Targeted Cancer Therapies
|
| 07/15/02 |
|
GenVec and BioReliance Sign Manufacturing Agreement
|
| 07/08/02 |
|
GenVec Elects William N. Kelley, M.D. to Board of Directors
|
| 06/18/02 |
|
GenVec Announces Mid-Year Update Conference Call
|
| 06/17/02 |
|
GenVec to Present at the Needham & Company First Annual Biotechnology Conference
|
| 06/03/02 |
|
GenVec Announces Completion of Patient Accrual in Phase II Clinical Trial of BioBypass in Peripheral Vascular Disease
|
| 05/30/02 |
|
Gene Therapy Clinical Results Show Notable Tumor Shrinkage In Phase I Human Trials
|
| 05/20/02 |
|
Diacrin Announces First Quarter Results
|
| 05/07/02 |
|
GenVec's Potent Antiangiogenic to Prevent Vision Loss Highlighted at Leading Ophthalmology Meeting
|
| 05/06/02 |
|
GenVec Announces Completion of Patient Accrual in Phase II Clinical Trial of BioBypass in Coronary Artery Disease
|
| 05/01/02 |
|
GenVec Announces First Quarter 2002 Financial Results
|
| 04/29/02 |
|
GenVec Elects Louis M. Sherwood, MD to Board of Directors
|
| 04/24/02 |
|
GenVec Completes Patient Accrual in Phase Ib Dose Escalation Trial of TNFerade in Solid Tumors
|
| 04/10/02 |
|
Diacrin Announces Year End Results
|
| 03/28/02 |
|
GenVec Announces Executive Promotions
|
| 03/12/02 |
|
GenVec Reports Fourth Quarter and Fiscal Year End 2001 Financial Results
|
| 02/28/02 |
|
GenVec to Present at BIO CEO & Investor Conference
|
| 02/15/02 |
|
GenVec Signs $10 Million Contract for Development of Preventative AIDS Vaccine
|
| 02/05/02 |
|
GenVec Announces End of Pfizer Partnership for Development of BioBypass(R)
|
| 01/24/02 |
|
GenVec to Present at Wachovia Securities Integrated Oncology Conference
|
| 01/15/02 |
|
GenVec, Inc. and National Institute of Allergy and Infectious Diseases To Develop Preventative AIDS Vaccine
|
| 01/10/02 |
|
GenVec Elects Harold R. Werner to Board of Directors
|
| 01/09/02 |
|
GenVec to Present at JP Morgan H&Q Annual Healthcare Conference
|
| 01/07/02 |
|
GenVec, Inc. Completes Private Placement of Common Stock
|
| 12/21/01 |
|
Arizona Man Undergoes State's First Skelatal Cell Transplant to Re-grow Damaged Heart Tissue
|
| 12/12/01 |
|
GenVec Year End Conference Call Tues. 12/11/01 9AM to 10 AM EST
|
| 12/06/01 |
|
GenVec Announces Presentation Of Final Data From Phase I Clinical Trials Of Biobypass In Peripheral Vascular Disease
|
| 11/13/01 |
|
Tnferade Gene Therapy Causes Tumor Shrinkage At Lowest Doses During Phase I Clinical Trials
|
| 11/06/01 |
|
GenVec Announces Third Quarter 2001 Financial Results
|
| 10/25/01 |
|
Diacrin Announces Third Quarter Results
|
| 10/24/01 |
|
GenVec To Present At The Ubs Warburg Global Life Sciences Conference
|
| 10/08/01 |
|
GenVec Expands Clinical Development Of Tnferade In Cancer - Interim Data To Be Presented In November. Human Testing Underway For Second Cancer Indication -
|
| 10/01/01 |
|
GenVec Elects John H. Landon To Board Of Directors
|
| 09/26/01 |
|
GenVec Announces Second Quarter 2001 Financial Results and Mid-Year Update
|
| 08/01/01 |
|
Diacrin Announces Second Quarter Results
|
| 07/24/01 |
|
GenVec And Varian Medical Systems Extend Collaborative Agreement Through 2004
|
| 06/20/01 |
|
Cleveland Man Second in Country to Undergo Skelatal Cell Transplant During Bypass Surgery
|
| 06/09/01 |
|
GenVec Receives U.S. Patent For The Improved Pharmaceutical Formulation Of Adenovectors
|
| 06/07/01 |
|
GenVec To Make Nine Presentations At The 2001 Annual Meeting Of The American Society Of Gene Therapy
|
| 05/29/01 |
|
UCLA Performs First Skeletal Muscle Cell Transplant into Heart during Bypass Surgery
|
| 05/29/01 |
|
GenVec Demonstrates Tissue-Specific Gene Delivery
|
| 05/24/01 |
|
GenVec Presents Preclincial Data On TNFerade(TM) At The 2001 Annual Meeting Of The American Society Of Clinical Oncology ("ASCO")
|
| 05/14/01 |
|
GenVec Reports First Quarter 2001 Financial Results
|
| 05/03/01 |
|
New 'Proof-of-Principle' Data Support The Potential Effectiveness Of GenVec's PEDF Product Candidate For Treating Macular Degeneration. Data Presented at the 2001 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
|
| 05/02/01 |
|
Albany Med Physicians First to Use Pig Cells in Spinal Cord Surgery
|
| 04/24/01 |
|
Diacrin Announces First QuarterResults
|
| 04/18/01 |
|
Genzyme and Diacrin Report Preliminary Results From Phase 2 Trial of NeuroCell(TM)-PD
|
| 03/16/01 |
|
GenVec Reports 2000 Financial Results
|
| 03/01/01 |
|
GenVec Initiates Clinical Trial With TNFERADE(TM) for the Treatment of Cancer
|
| 02/15/01 |
|
GenVec Expands its Angiogenesis Technology for the Prevention of Blindness
|
| 02/12/01 |
|
Diacrin Announces Year End Results
|
| 02/06/01 |
|
GenVec Announces Update on Partnership with Warner-Lambert on Biopass(R) Angiogen
|
| 01/25/01 |
|
GenVec Elects Wayne T. Hockmeyer to its Board of Directors
|
| 01/22/01 |
|
Diacrin Promotes E. Michael Egan to Chief Operating Officer
|
| 01/02/01 |
|
GenVec Raises $38 Million in it's Initial Public Stock Offering.
|
| 12/12/00 |
|
Diacrin Announces Third Quarter Results
|
| 10/17/00 |
|
GenVec, Inc. Files Registration Statement for Proposed Initial Public Offering
|
| 10/05/00 |
|
First Ever Transplantation of Skeletal Muscle Cells Into Patient's Heart to Test Whether the Cells Can Repair Damaged Heart Muscle
|
| 10/04/00 |
|
GenVec Announces Start of Phase II Trials with BIOBYPASS for Peripheral Vascular Disease
|
| 08/10/00 |
|
GenVec Announces Broad Gene Therapy Patent
|
| 08/02/00 |
|
Diacrin Announces Second Quarter Results
|
| 07/24/00 |
|
Diacrin/Genzyme Joint Venture and FDA Agree to Maximize Product Efficacy Data in Ongoing NeuroCell?-PD Blinded Phase 2 Clinical Trial
|
| 07/14/00 |
|
Genvec Receives $2 Million for Development of New Gene Therapy Production Process
|
| 06/06/00 |
|
Genvec Announces Initiation of Phase II Human Clinical Trials with Experimental Therapy for Heart Disease
|
| 04/26/00 |
|
Diacrin Suspends Phase 1 Clinical Trial for Stroke
|
| 04/17/00 |
|
Diacrin Announces Exercise of Over-Allotment Option
|
| 03/28/00 |
|
Diacrin Announces Pricing of Public Offering
|
| 03/23/00 |
|
Genvec Announces New Approach for Treating Blindness
|
| 02/22/00 |
|
Genvec Launches Comprehensive Web Site
|
| 02/14/00 |
|
Genvec Opens New Headquarters
|
| 02/07/00 |
|
Cantab Completes Option and License Agreement with GenVec - Companies Forge Leading Position in Neurological Gene Delivery
|
| 12/08/99 |
|
Fetal Pig Cells Implanted in Stroke Patient
|
| 09/22/99 |
|
GenVec, Inc. Annnounces Key Additions to its Senior Management Team
|
| 05/25/99 |
|
Three New Patents Added to GenVec
|
| 03/29/99 |
|
Diacrin Announces Year End Results
|
| 02/23/99 |
|
Diacrin Files Registration Statement for Public Offering
|
| 02/23/99 |
|
GenVec, Inc. Announces Patent for Gene Delivery Systems to Target Specified Tissues
|
| 02/23/99 |
|
GenVec, Inc. Announces Patent of Improved Gene Delivery Vectors for Use in Gene Therapy
|
| 02/18/99 |
|
GenVec, Inc. Announces the Release of Initial Findings of a Phase I Clinical TrialTrial Evaluates the Safety of AdGVVEGF121.10* For use in Cardiac Revascularization
|
| 11/10/98 |
|
GenVec Announces U.S. Patent for Production of Advanced Gene Therapy Vectors
|
| 11/02/98 |
|
GenVec, Inc. Licenses the Tumor Necrosis Factor Alpha Gene for All Gene Therapy Applications
|
| 04/30/98 |
|
GenVec and Fuso Announce Cancer Research Collaboration
|
| 04/20/98 |
|
Varian and GenVec Reach Agreement to Jointly Develop New Therapy ProductCollaboration On Combining Radiotherapy With Novel Gene Constructs Aimed At Enhanced Therapy Techniques, New Products for Fighting Cancer
|
| 04/07/98 |
|
GenVec Receives U.S. Patent for Advanced Gene Therapy Vectors
|
| 03/31/98 |
